León CC, Quesada AC, Fuentes AF, Hernández VA

Language: Spanish
References: 25
Page: 28-35
PDF size: 443.62 Kb.

ABSTRACT

Primary Sjögren’s syndrome is a systemic autoimmune disease that mainly affects exocrine glands and confers an increased risk of developing lymphomas compared with the general population and even with other autoimmune diseases. It is the most severe comorbidity that occurs in this entity, which increases its mortality. Clinical, serological and histological characteristics have been studied to predict the development of these lymphoproliferative disorders. The most common symptom in this group is unilateral parotid enlargement and they are mainly non-Hodgkin’s lymphomas, extranodal marginal lymphoma, derived from mucosa-associated lymphoid tissue or MALT type being the most common between them. It is believed that its development is due to antigenic stimulation of reactive and polyclonal B cells which causes expansion and transition to monoclonal B cells, and together with activation of signaling pathways perpetuates cell proliferation; currently, target therapy directed against the activation of these cells is being studied. Most of these lymphomas have an indolent course and are localized, so they just need surveillance, in case of aggressive or disseminated disease the use of polychemotherapy plus rituximab is preferred.

REFERENCES

1. Mariette X Criswell LA. Primary Sjögren’s syndrome. N Engl J Med. 2018;378(10):931-939.

2. Nocturne G Pontarini E Bombardieri M Mariette X. Lymphomas complicating primary Sjögren’s syndrome: from autoimmunity to lymphoma. Rheumatology. 2019;1-9.

3. Bijilsma J Hachulla E. EULAR Textbook on Rheumathic Diseases. BMJ Publishing Group Ltd. London - UK. 3rd Edition. 2018;733-762.

4. Liang Y Yang Z Qin B Zhong R. Primary Sjögren’s syndrome and malignancy risk: a systemic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-1156.

5. Nocturne G Mariette X. B cells in the pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol. 2018;14(3):1-13.

6. Hu S Zhou S Wu Y Zhao Y Wang S Hang B et al. Autoinmmune disease-associated non-Hodgkin’s lymphoma-a large retrospective study from China. Ann Hematol. 2019;98(2):445-455.

7. Alunno A Leone MC Giacomelli R Gerli R Carubbi F. Lymphoma and lymphomagenesis in primary Sjögren’s syndrome. Front Med. 2018; 5(102):1-7.

8. Tesher MS Esteban Y Henderson TO Villanueva G Onel KB. Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association with Pediatric Primary Sjögren Syndrome: 2 Cases and Review. J Pediatr Hematol Oncol. 2018;1-4.

9. Schenone LN Pellet AC Mamani M Melo F Adrover M Barreira J et al. Development of lymphoma in patients with primary Sjögren’s syndrome. Int J Clin Rheumtol. 2019;14(2):69-74.

10. Pacheco A. Epidemiología del Síndrome de Sjögren Primario en la consulta externa del Servicio de Reumatología del Hospital Dr. Rafael Ángel Calderón Guardia, Segundo Semestre del 2011. Trabajo de investigación. 2012; 1-40.

11. Firestein GS Budd R Gabriel SE McInnes IB O’Dell JR. Kelley and Firestein’s Textbook of Rheumatology. 10th edition. Elsevier Health Sciences. PA-USA. 2017;547-551.

12. Goules AV Tzioufas AG. Lymphomagenesis in Sjögren’s syndrome: Predictive biomarkers towards precision medicine. Autoimmun Rev. 2018;18(2):137-143.

13. Fragkioudaki S Mavragani CP Moutsopoulos HM. Predicting the risk for lymphoma development in Sjögren syndrome: an easy tool for clinical use. Medicine. 2016; 95(25):1-8.

14. Quartuccio L Isola M Baldini C et al. Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun. 2014;51:75-80.

15. Retamozo S Gheitasi H Quartuccio L et al. Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology. 2016;55(8):1443–1451.

16. Haacke EA Van der Vegt B Vissink A Spijkervet FK Bootsma H Kroese FG. Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren’s syndrome are not predictive for parotid MALT lymphoma development. Ann Rheum Dis. 2017;76(10):1781-1784.

17. Brito-Zerón P Kostov B Fraile G et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017;10(1):1-12.

18. Chiu Y H Chung CH Lin KT et al. Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study. Oncotarget. 2017;8(30):50098.

19. Papageorgiou A Ziogas DC Mavragani CP et al. Predicting the outcome of Sjogren’s syndrome-associated non-Hodgkin’s lymphoma patients. PLoS One. 2015;10(2):1-16.

20. Risselada AP Kruize AA Bijlsma JW. Clinical features distinguishing lymphoma development in primary Sjögren’s syndrome—a retrospective cohort study. Semin Arthritis Rheum. 2013;43(2):171-177.

21. Nocturne G Virone A Ng WF Le Guern V Hachulla E Cornec D et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol. 2016;68(4):977-985.

22. Nocturne G Mariette X. Sjögren syndrome associated lymphomas: an update on pathogenesis and management. Br J of Haematol. 2015;168(3):317-327.

23. Giannouli S Voulgarelis M. Predicting progression to lymphoma in Sjögren’s syndrome patients. Expert Rev Clin Immunol. 2014;10(4):501-512.

24. Hemminki K Liu X Ji J Försti A. Origin of B-cell neoplasms in autoimmune disease. PloS one. 2016;11(6):1-7.

25. Navarro-Mendoza EP Aguirre-Valencia D Posso- Osorio I et al. Cytokine markers of B lymphocytes in minor salivary gland infiltrates in Sjögren’s syndrome. Autoimmun Rev. 2018;17(7):709-714.